Drug Treatment

Browse more sub-categories

Active Resources: 29

Image Library

Patient Information

Articles: 6

  • Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

    Susa Coffey's picture

    The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of ≤100,000 copies/mL. The dosage is 25 mg...

  • Pyrimethamine Availability

    Susa Coffey's picture

    Pyrimethamine is no longer available in retail pharmacies in the United States, though it is available through a commercial specialty pharmacy program (the application process, approval, and delivery of the medication will take at least 2 days; for information on ordering, click...

  • START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV

    Jennifer Cocohoba's picture

    The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...

  • TAF: New Data on Tenofovir Alafenamide Fumarate

    Susa Coffey's picture

    Tenofovir alafenamide fumarate (TAF) is an investigational prodrug of tenofovir that in studies to date appears to have less renal and bone toxicity than the current tenofovir product, tenofovir disoproxil fumarate (TDF). This is because TAF is metabolized to tenofovir in lymphocytes and...

  • Adult and Adolescent Guidelines: Major Changes

    Susa Coffey's picture

    The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy. 

    Efavirenz/TDF/FTC (Atripla) has...
  • Two New Boosted-PI Coformulations

    Susa Coffey's picture

    Two boosted protease inhibitor (PI) coformulations have just been approved by the FDA. These are:

    Darunavir 800 mg + cobicistat 150 mg (Prezcobix), andAtazanavir 300 mg + cobicistat 150 mg (Evotaz)

    In these fixed-dose combinations, cobicistat is used as the pharmacokinetic booster of the PI...

Day Title
HIV Pre-Exposure and Post-Exposure Prophylaxis (PrEP and PEP)
Event type: Webinars
24th Annual HIV Clinical Update for Nurses: HIV Treatment Update
Day Title
The Basics of Providing HIV Care and Treatment
American Pharmacists Association Annual Meeting and Exposition 2017
Pharmacists as Patient Educators
Event type: Webinars